Shineco, Inc. (SISI)
USD 0.87
(-3.32%)
USD 0.87
(-3.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 84.17 Million USD | 32.63% |
| 2023 | 63.46 Million USD | -0.56% |
| 2022 | 63.82 Million USD | 4.09% |
| 2021 | 61.31 Million USD | -22.47% |
| 2020 | 79.08 Million USD | -5.55% |
| 2019 | 83.73 Million USD | 0.77% |
| 2018 | 83.1 Million USD | 21.7% |
| 2017 | 68.28 Million USD | 19.7% |
| 2016 | 57.04 Million USD | 9.43% |
| 2015 | 52.13 Million USD | 23.47% |
| 2014 | 42.22 Million USD | 38.1% |
| 2013 | 30.57 Million USD | 0.0% |
| 2006 | 4.36 Million USD | 0.0% |
| 2005 | 4.36 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 84.17 Million USD | -17.36% |
| 2024 Q3 | 101.86 Million USD | -0.57% |
| 2024 Q2 | 102.45 Million USD | 4.71% |
| 2024 Q1 | 97.84 Million USD | 54.16% |
| 2023 Q2 | 59.06 Million USD | 2.86% |
| 2023 Q4 | 63.46 Million USD | -6.29% |
| 2023 Q3 | 67.72 Million USD | 14.68% |
| 2023 FY | 63.46 Million USD | -0.56% |
| 2023 Q1 | 57.42 Million USD | -10.04% |
| 2022 Q3 | 71.87 Million USD | -3.85% |
| 2022 Q1 | 68.26 Million USD | 11.32% |
| 2022 FY | 63.82 Million USD | 4.09% |
| 2022 Q2 | 74.75 Million USD | 9.51% |
| 2022 Q4 | 63.82 Million USD | -11.2% |
| 2021 Q2 | 73.74 Million USD | -11.37% |
| 2021 Q3 | 67.59 Million USD | -8.34% |
| 2021 FY | 61.31 Million USD | -22.47% |
| 2021 Q4 | 61.31 Million USD | -9.28% |
| 2021 Q1 | 83.2 Million USD | 5.21% |
| 2020 FY | 79.08 Million USD | -5.55% |
| 2020 Q3 | 78.89 Million USD | -5.03% |
| 2020 Q4 | 79.08 Million USD | 0.24% |
| 2020 Q1 | 81.14 Million USD | -3.1% |
| 2020 Q2 | 83.07 Million USD | 2.37% |
| 2019 Q1 | 81.12 Million USD | -2.38% |
| 2019 Q2 | 82.52 Million USD | 1.73% |
| 2019 Q3 | 85.32 Million USD | 3.4% |
| 2019 Q4 | 83.73 Million USD | -1.86% |
| 2019 FY | 83.73 Million USD | 0.77% |
| 2018 Q2 | 78.88 Million USD | 10.67% |
| 2018 Q3 | 89.26 Million USD | 13.16% |
| 2018 Q4 | 83.1 Million USD | -6.9% |
| 2018 FY | 83.1 Million USD | 21.7% |
| 2018 Q1 | 71.27 Million USD | 4.38% |
| 2017 FY | 68.28 Million USD | 19.7% |
| 2017 Q4 | 68.28 Million USD | 4.09% |
| 2017 Q3 | 65.6 Million USD | 2.87% |
| 2017 Q2 | 63.77 Million USD | -1.46% |
| 2017 Q1 | 64.71 Million USD | 13.45% |
| 2016 Q4 | 57.04 Million USD | 0.76% |
| 2016 Q3 | 56.61 Million USD | 2.57% |
| 2016 Q2 | 55.2 Million USD | 6.68% |
| 2016 Q1 | 51.74 Million USD | -0.75% |
| 2016 FY | 57.04 Million USD | 9.43% |
| 2015 Q2 | 48.17 Million USD | 0.0% |
| 2015 Q4 | 52.13 Million USD | 2.91% |
| 2015 Q3 | 50.65 Million USD | 5.15% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 52.13 Million USD | 23.47% |
| 2014 Q3 | 40.8 Million USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 FY | 42.22 Million USD | 38.1% |
| 2014 Q4 | 42.22 Million USD | 3.47% |
| 2013 FY | 30.57 Million USD | 0.0% |
| 2013 Q4 | 30.57 Million USD | 0.0% |
| 2007 Q2 | 4.6 Million USD | 5.66% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q1 | 4.36 Million USD | 0.0% |
| 2006 FY | 4.36 Million USD | 0.0% |
| 2006 Q3 | 5.04 Million USD | 0.0% |
| 2006 Q1 | 4.69 Million USD | 0.0% |
| 2005 FY | 4.36 Million USD | 0.0% |
| 2005 Q3 | 4.53 Million USD | 4.05% |
| 2005 Q2 | 4.36 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 90.692% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -46.608% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 92.637% |
| Cosmos Health Inc. | 66.29 Million USD | -26.976% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -535.434% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 59.096% |
| Cronos Group Inc. | 1.13 Billion USD | 92.578% |
| Incannex Healthcare Limited | 17.04 Million USD | -393.808% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -50.457% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 69.244% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -897.597% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -207.82% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -207.82% |
| SCYNEXIS, Inc. | 128.41 Million USD | 34.446% |
| Safety Shot Inc | 12.7 Million USD | -562.351% |
| Theratechnologies Inc. | 77.76 Million USD | -8.243% |
| Alpha Teknova, Inc. | 128.58 Million USD | 34.535% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -57.973% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 94.653% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -465.228% |
| Dynavax Technologies Corporation | 997.09 Million USD | 91.558% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 82.13% |
| Radius Health, Inc. | 1.71 Billion USD | 95.094% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -263.987% |
| Alvotech | 950.09 Million USD | 91.14% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 88.442% |
| SIGA Technologies, Inc. | 254.83 Million USD | 66.967% |
| Silver Spike Investment Corp. | 88.57 Million USD | 4.964% |
| Journey Medical Corporation | 76.84 Million USD | -9.539% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -149.082% |
| Embecta Corp. | 1.21 Billion USD | 93.068% |
| Harrow Health, Inc. | 311.75 Million USD | 72.998% |
| Procaps Group, S.A. | 460.18 Million USD | 81.708% |
| Biofrontera Inc. | 27.93 Million USD | -201.373% |
| DURECT Corporation | 45.18 Million USD | -86.283% |
| PainReform Ltd. | 9.93 Million USD | -747.728% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 94.025% |
| OptiNose, Inc. | 107.72 Million USD | 21.86% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -265.249% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 81.701% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -2.939% |
| ProPhase Labs, Inc. | 91.92 Million USD | 8.428% |
| Phibro Animal Health Corporation | 982.18 Million USD | 91.429% |
| Procaps Group S.A. | 460.18 Million USD | 81.708% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -94.369% |
| Viatris Inc. | 47.68 Billion USD | 99.823% |
| Rockwell Medical, Inc. | 52.17 Million USD | -61.347% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 28.719% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.058% |
| PetIQ, Inc. | 868.22 Million USD | 90.304% |
| Talphera, Inc. | 20.39 Million USD | -312.745% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.411% |
| Alimera Sciences, Inc. | 153.52 Million USD | 45.169% |
| Assertio Holdings, Inc. | 286.41 Million USD | 70.61% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1314.367% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 67.763% |
| Hempacco Co., Inc. | 18.04 Million USD | -366.547% |
| Alvotech | 950.09 Million USD | 91.14% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 94.902% |
| Kamada Ltd. | 351.96 Million USD | 76.083% |
| Currenc Group, Inc. | 141.49 Million USD | 40.505% |
| Indivior PLC | 1.95 Billion USD | 95.686% |
| Evoke Pharma, Inc. | 7.06 Million USD | -1090.901% |
| Flora Growth Corp. | 23.62 Million USD | -256.3% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -535.434% |
| Evolus, Inc. | 188.99 Million USD | 55.46% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 93.422% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 94.436% |
| Akanda Corp. | 8.83 Million USD | -852.256% |